文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

GARP:TGF-β1阻断在小鼠原发性骨髓纤维化中的治疗活性

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.
PubMed 文献 · Blood · 2023-01-01

研究在小鼠原发性骨髓纤维化(PMF)模型中探讨GARP:TGF-β1阻断的治疗作用。发现PMF小鼠骨髓和脾脏GARP表达增加,阻断GARP:TGF-β1不仅减少纤维化还抑制转化细胞克隆扩增;通过条件性敲除小鼠证明疗效依赖靶向调节性T细胞(Tregs)上的GARP,且该效应伴随脾脏IFN-γ信号增加,在CD8 T细胞清除后消失。结果提示选择性阻断GARP表达Tregs激活TGF-β1可增强CD8 T细胞介导的免疫反应限制转化细胞扩增,为骨髓增殖性肿瘤提供可测试的新方法。

要点

  • PMF小鼠骨髓和脾脏GARP表达增加,GARP:TGF-β1阻断减少纤维化和转化细胞克隆扩增。
  • GARP在Tregs或巨核细胞条件性敲除实验显示疗效依赖靶向Tregs上的GARP。
  • 疗效伴随脾脏IFN-γ信号增加,CD8 T细胞清除后疗效丧失。

核心结论

  • 选择性阻断GARP表达Tregs激活TGF-β1可增强CD8 T细胞介导的免疫反应限制转化细胞扩增。
  • 该策略为治疗骨髓增殖性肿瘤提供可测试的新方法。

研究设计与样本

  • 研究在小鼠PMF模型中检测GARP表达并测试阻断GARP:TGF-β1的单克隆抗体疗效。
  • 使用在Tregs或巨核细胞中Garp基因敲除的小鼠明确靶细胞。
  • 通过CD8 T细胞清除实验验证免疫机制。

主要发现

  • PMF小鼠骨髓和脾脏GARP表达增加。
  • GARP:TGF-β1阻断减少纤维化并抑制转化细胞克隆扩增。
  • GARP在Tregs或巨核细胞敲除实验表明疗效依赖靶向Tregs上的GARP。
  • 疗效伴随脾脏IFN-γ信号增加,CD8 T细胞清除后疗效丧失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by the clonal expansion of myeloid cells, notably megakaryocytes (MKs), and an aberrant cytokine production leading to bone marrow (BM) fibrosis and insufficiency. Current treatment options are limited. TGF-β1, a profibrotic and immunosuppressive cytokine, is involved in PMF pathogenesis. While all cell types secrete inactive, latent TGF-β1, only a few activate the cytokine via cell type-specific mechanisms. The cellular source of the active TGF-β1 implicated in PMF is not known. Transmembrane protein GARP binds and activates latent TGF-β1 on the surface of regulatory T lymphocytes (Tregs) and MKs or platelets. Here, we found an increased expression of GARP in the BM and spleen of mice with PMF and tested the therapeutic potential of a monoclonal antibody (mAb) that blocks TGF-β1 activation by GARP-expressing cells. GARP:TGF-β1 blockade reduced not only fibrosis but also the clonal expansion of transformed cells. Using mice carrying a genetic deletion of Garp in either Tregs or MKs, we found that the therapeutic effects of GARP:TGF-β1 blockade in PMF imply targeting GARP on Tregs. These therapeutic effects, accompanied by increased IFN-γ signals in the spleen, were lost upon CD8 T-cell depletion. Our results suggest that the selective blockade of TGF-β1 activation by GARP-expressing Tregs increases a CD8 T-cell-mediated immune reaction that limits transformed cell expansion, providing a novel approach that could be tested to treat patients with myeloproliferative neoplasms.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lecomte S, Devreux J, de Streel G, et al. Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis. Blood. 2023. PMID: 36322928. doi:10.1182/blood.2022017097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。